Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week

R. Ferreiro-Iglesias, A. Jardi, A. Quiroga, I. Baston, J. Gonzalez, J. M. Giraldez, I. Zarra, M. J. Lamas, J. E. Dominguez-Munoz, M. Barreiro-de Acosta

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S390-S391
JournalJournal of Crohn's and Colitis
Publication statusPublished - Mar 2019

Cite this